Want to see LAB full AI Analyst Report?
Top Page
Standard BioTools
(NASDAQ:LAB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.88
▲(5.42% Upside)
Action:Reiterated
Date:07/28/26
LAB scores low primarily due to weakening financial performance: sharply declining TTM revenue, extremely large operating losses, and persistent negative free cash flow despite a low-leverage balance sheet. Technicals also detract, with the stock trading below all major moving averages. Corporate actions (merger/asset divestiture and related cash proceeds) provide some strategic support, but are tempered by renewed Nasdaq bid-price compliance risk; valuation signals are limited by the negative P/E and lack of dividend data.
Positive Factors
Balance Sheet Strength
Low leverage and a sizable equity base provide durable financial flexibility. With minimal debt and expanded equity, the company can fund operations, pursue strategic transactions, or absorb continued operating losses without immediate refinancing stress, extending runway versus peers.
Negative Factors
Negative Cash Generation
Persistent material cash burn undermines long-term self-sufficiency. Sustained negative operating and free cash flow forces reliance on balance sheet resources, asset monetizations or external financing, constraining investment in R&D, commercialization and margin recovery initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Low leverage and a sizable equity base provide durable financial flexibility. With minimal debt and expanded equity, the company can fund operations, pursue strategic transactions, or absorb continued operating losses without immediate refinancing stress, extending runway versus peers.
Read all positive factors
Standard BioTools Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how sales are split across the company’s business lines (for example instruments, consumables and services, and major geographies). A larger share of consumables and services usually means steadier, higher-margin recurring revenue, while dependence on one-time instrument sales signals more revenue volatility and capital intensity — so the split reveals growth sustainability, margin profile, and exposure to demand cycles.
Shows how sales are split across the company’s business lines (for example instruments, consumables and services, and major geographies). A larger share of consumables and services usually means steadier, higher-margin recurring revenue, while dependence on one-time instrument sales signals more revenue volatility and capital intensity — so the split reveals growth sustainability, margin profile, and exposure to demand cycles.
Data provided by:
The Fly
The FlyStandard BioTools (LAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$351.26M
Dividend YieldN/A
Average Volume (3M)3.82M
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue Growth-49.17%
EPS Growth31.01%
CountryUS
Employees389
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-0.25
Shares Outstanding391,462,920
10 Day Avg. Volume1,722,820
30 Day Avg. Volume3,820,955
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.15
Price to Sales (P/S)5.72
P/FCF Ratio-5.91
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.35Price Target Upside62.65% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$82.50M
Standard BioTools Business Overview & Revenue Model
Company Description
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle Ea...
How the Company Makes Money
Standard BioTools generates revenue primarily by selling life science research products tied to its instrument platforms. Key revenue streams include: (1) Instrument sales: one-time sales of hardware systems (e.g., mass cytometry and other analyti...
Standard BioTools Earnings Call Summary
Earnings Call Date:May 06, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a well-managed quarter with robust strategic initiatives and strong cost management, despite facing significant revenue declines and challenges in the U.S. academic market. The company's strong cash position and strategic product expansions provide a positive outlook, though the impact of tariffs and revenue declines remain concerns.Positive Updates
Strategic Product Launches and Expansions
Standard BioTools announced a new SomaScan offering and expanded its reach with the NGS-based Illumina partner solution, enhancing translational and clinical research capabilities.
Negative Updates
Revenue Decline
Total revenue fell by 10% year-over-year, with consumables down by 16% and services down by 16%, due to lower volumes and project timing.
Read all updates
Q1-2025 Updates
Positive
Negative
Strategic Product Launches and Expansions
Standard BioTools announced a new SomaScan offering and expanded its reach with the NGS-based Illumina partner solution, enhancing translational and clinical research capabilities.
Read all positive updates
Company Guidance
During the Standard BioTools first quarter 2025 earnings call, the company reiterated its full-year revenue guidance of $165 million to $175 million, despite a 10% year-over-year decline in Q1 revenue to $40.8 million. The decline was primarily due to lower consumables and services revenue, with consumables down 16% and services down 16% year-over-year. Instrument sales, however, grew by 24%, driven by the Hyperion XTi system. The company reported non-GAAP gross margins of 53.2%, impacted by lower volumes and product mix, and a non-GAAP operating loss improvement of 45% year-over-year. Adjusted EBITDA loss improved 29% to $16.9 million, and cash burn was reduced by 33%. The company emphasized its strategic focus on proteomics and highlighted new product launches, including the CyTOF-XT Pro and SomaScan Select Asset, as key drivers for future growth.Standard BioTools Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.25M | 85.33M | 174.43M | 106.34M | 97.95M | 130.58M |
| Gross Profit | 41.66M | 42.54M | 84.26M | 50.45M | 37.05M | 69.37M |
| EBITDA | -81.51M | -89.69M | -118.14M | -54.46M | -173.57M | -44.27M |
| Net Income | -94.08M | -74.90M | -138.88M | -74.66M | -190.10M | -59.24M |
Balance Sheet | ||||||
| Total Assets | 639.11M | 567.75M | 612.34M | 323.07M | 390.31M | 275.21M |
| Cash, Cash Equivalents and Short-Term Investments | 455.18M | 187.57M | 292.87M | 114.89M | 165.78M | 28.45M |
| Total Debt | 29.49M | 30.83M | 33.00M | 98.21M | 102.66M | 111.65M |
| Total Liabilities | 77.99M | 143.46M | 140.62M | 471.12M | 471.78M | 180.62M |
| Stockholders Equity | 561.12M | 424.29M | 471.72M | -148.05M | -81.47M | 94.60M |
Cash Flow | ||||||
| Free Cash Flow | -94.48M | -82.65M | -151.81M | -46.12M | -93.19M | -57.33M |
| Operating Cash Flow | -90.66M | -74.35M | -143.45M | -43.29M | -89.37M | -44.06M |
| Investing Cash Flow | 201.23M | 24.77M | 363.17M | 20.24M | -88.13M | -11.95M |
| Financing Cash Flow | 576.00K | 570.00K | -102.62M | -6.81M | 230.76M | 15.96M |
Standard BioTools Technical Analysis
Neutral
0.83
Price Trends
0.91
Negative
0.93
Negative
1.13
Negative
Market Momentum
-0.01
Negative
45.80
Neutral
30.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Neutral. The current price of 0.83 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 0.91, and below the 200-day MA of 1.13, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 45.80 is Neutral, neither overbought nor oversold. The STOCH value of 30.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LAB.
Standard BioTools Risk Analysis
Standard BioTools disclosed 50 risk factors in its most recent earnings report. Standard BioTools reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Standard BioTools Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $1.97B | 20.31 | 32.81% | ― | 34.41% | 90.73% | |
69 Neutral | $812.54M | -42.46 | -4.15% | ― | 3.18% | -100.37% | |
54 Neutral | $1.31B | -12.41 | -43.52% | ― | -24.71% | 21.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $507.19M | -2.39 | -32.59% | ― | -3.16% | 72.02% | |
47 Neutral | $556.08M | -5.87 | -6.70% | ― | 6.83% | -69.59% | |
45 Neutral | $351.26M | -3.47 | -20.80% | ― | -49.17% | 31.01% |
* Healthcare Sector Average
LAB
Standard BioTools
0.87
-0.45
-34.24%
MYGN
Myriad Genetics
2.86
-1.12
-28.14%
CDNA
CareDx
43.71
31.11
246.90%
FLGT
Fulgent Genetics
16.55
-1.81
-9.86%
PSNL
Personalis
12.66
7.09
127.29%
CSTL
Castle Biosciences
28.00
12.68
82.77%
Standard BioTools Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Standard BioTools Divests Mass Cytometry to Multiplex Bio
Positive
Jul 28, 2026
On July 24, 2026, Standard BioTools agreed a termination and waiver deal with Illumina under which it received about $30 million in cash in exchange for relinquishing a 2026 earnout and future royalty rights tied to Illumina’s earlier acquis...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Standard BioTools Receives Nasdaq Bid Price Deficiency Notice
Negative
Jul 24, 2026
On July 22, 2026, Standard BioTools disclosed that it had received a notice from Nasdaq stating the company no longer meets the exchange’s minimum $1.00 bid price requirement, after its shares closed below that level for 30 consecutive busin...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Standard BioTools Shareholders Approve 2026 Equity Incentive Plans
Positive
Jun 18, 2026
Standard BioTools Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026, where shareholders approved the company’s 2026 Equity Incentive Plan and an amendment to the Amended and Restated 2017 Employee Stock Purchase Plan, adding...
Business Operations and StrategyM&A TransactionsStock Split
Standard BioTools to Merge with Treeline Biosciences
Positive
Jun 8, 2026
On June 6, 2026, Standard BioTools agreed to merge with Treeline Biosciences in an all-stock transaction valuing Treeline at about $2.5 billion and Standard BioTools at roughly $460 million, creating a company in which Treeline shareholders will o...
Delistings and Listing ChangesRegulatory Filings and Compliance
Standard BioTools Regains Nasdaq Minimum Bid Compliance Status
Positive
Jun 5, 2026
On June 5, 2026, Standard BioTools Inc. announced it had received a letter from Nasdaq’s Listing Qualifications Department confirming the company had regained compliance with the exchange’s minimum bid price requirement. The notificati...
Executive/Board Changes
Standard BioTools Grants RSUs to Chief Business Officer
Neutral
Jun 3, 2026
On May 29, 2026, Standard BioTools’ Human Capital Committee approved a grant of 500,000 restricted stock units to Chief Business Officer Sean Mackay under the company’s 2026 Equity Incentive Plan, with the award becoming effective on J...
Business Operations and StrategyExecutive/Board Changes
Standard BioTools Adopts New Executive Severance Protection Plans
Positive
May 28, 2026
On May 21, 2026, Standard BioTools’ board approved a 2026 Change of Control and Severance Plan for its executive leadership team, excluding the CEO, with a term through August 4, 2028 and enhanced protections for qualifying terminations. The...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Standard BioTools Highlights Improved Q1 2026 Results, Outlook
Positive
May 5, 2026
Standard BioTools reported first quarter 2026 revenue of $21.1 million, up 5% year over year, driven by 35% growth in consumables to $11.0 million, while instruments revenue declined 33% to $4.5 million amid capital-constrained end markets. The co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.